ArticleFrontiers in medicine2017
Hepatoid Adenocarcinoma of the Stomach: A Challenging Diagnostic and Therapeutic Disease through a Case Report and Review of the Literature.
Article in Frontiers in medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Integrative analysis reveals a clinicogenomic landscape associated with liver metastasis and poor prognosis in hepatoid adenocarcinoma of the stomach.International journal of biological sciences · 2022Pooled it
- Pathologic complete response of advanced hepatoid adenocarcinoma of the stomach following immuno-chemotherapy and conversion surgery: a rare case report and review of the literature.Frontiers in oncology · 2025Article
- Clinicopathological characteristics and prognostic outcomes of resectable hepatoid adenocarcinoma of the stomach: insights from a multicenter case-control study.American journal of cancer research · 2025Article
- Alpha-Fetoprotein-Producing Hepatoid Adenocarcinoma of the Stomach.Journal of medical cases · 2024Article
- Clinicopathological features of hepatoid adenocarcinoma of the stomach: A multicenter retrospective study.Cancer reports (Hoboken, N.J.) · 2024Article
- Unusual or Uncommon Histology of Gastric Cancer.Journal of gastric cancer · 2024Review
- Primary Peritoneal Hepatoid Adenocarcinoma Patients Treated by Complete Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).Indian journal of surgical oncology · 2023Article
- Emphasis on the clinical relationship between alpha-fetoprotein and hepatoid adenocarcinoma of the stomach: a retrospective study.BMC gastroenterology · 2023Article
- Prognostic significance of preoperative serum tumor markers in hepatoid adenocarcinoma of stomach (HAS).BMC cancer · 2023Article
- Hepatoid adenocarcinoma: A wolf in hepatocellular carcinoma's clothing.JGH open : an open access journal of gastroenterology and hepatology · 2022Article
- Cardiac tamponade due to perforation of aBMJ case reports · 2022Article
- Assessment of Clinicopathological Characteristics and Development of an Individualized Prognostic Model for Patients With Hepatoid Adenocarcinoma of the Stomach.JAMA network open · 2021Article
- Gastric hepatoid carcinoma: Report of a case.Northern clinics of Istanbul · 2021Article
- Gastric hepatoid adenocarcinoma with multiple liver metastasis: a case report.Gastroenterology and hepatology from bed to bench · 2021Article
- Hepatoid Adenocarcinoma of the Stomach: Current Perspectives and New Developments.Frontiers in oncology · 2021Review
- The prognosis of hepatoid adenocarcinoma of the stomach: a propensity score-based analysis.BMC cancer · 2020Article
- Hepatoid Adenocarcinoma Presenting as Pancreatitis.ACG case reports journal · 2020Article
- Therapeutic Approaches to Gastric Hepatoid Adenocarcinoma: Current Perspectives.Therapeutics and clinical risk management · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatoid adenocarcinoma of the stomach (HAS) is a rare aggressive tumor with hepatocellular differentiation. HAS often produces alpha fetoprotein (AFP) and metastasizes to the lymph nodes and the liver. Molecular studies revealed
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.